Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03115112 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
A Phase 3 study, sponsored by Theracos.
- Completed
- Registry status
- Phase 3
- Development phase
- 386
- Enrollment target
NCT03115112 is a Phase 3 study that has completed, run by Theracos. The registered enrollment target is 386 participants.
The verdict
NCT03115112, a Phase 3 study, has completed, sponsored by Theracos.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 386 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the effect of bexagliflozin compared to sitagliptin as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
Interventions
- DRUG Sitagliptin
- DRUG Bexagliflozin
- DRUG Placebo for sitagliptin
- DRUG Placebo for bexagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 386 participants |
| Start Date | 2017-10-12 |
| Est. Completion | 2018-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03115112
The ClinicalTrials.gov registry entry for NCT03115112 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 386 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theracos, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Sitagliptin is the first listed.
NCT03115112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03115112 about?
NCT03115112 is a clinical study titled "Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects". The purpose of this study is to investigate the effect of bexagliflozin compared to sitagliptin as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
What is the current status of trial NCT03115112?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 386 participants. The study started on 2017-10-12. Estimated completion is 2018-10-31.
What interventions are being tested in trial NCT03115112?
The interventions under investigation include: Sitagliptin (DRUG), Bexagliflozin (DRUG), Placebo for sitagliptin (DRUG), Placebo for bexagliflozin (DRUG).
Who is sponsoring clinical trial NCT03115112?
This trial is sponsored by Theracos, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.